Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Christine L HathawayDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States.ORCID 0009-0006-7332-1480
Elizabeth R BrownVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0003-4286-2111
Stephen CherneDepartment of Laboratory Medicine and Pathology, Harborview Medical Center, Seattle, WA, United States.
Alyssa L SepulvedaUniversity of Texas Rio Grande Valley School of Medicine, Edinburg, TX, United States.
Zvavahera M ChirenjeDepartment of Obstetrics/Gynecology and Reproductive Science, University of California San Francisco, San Francisco, CA, United States.ORCID 0000-0003-3538-5150
Nitesha JeenarainSouth African Medical Research Council, HIV and Other Infectious Diseases Research Unit, Durban, South Africa.
Logashvari NaidooSouth African Medical Research Council, HIV and Other Infectious Diseases Research Unit, Durban, South Africa.
Samantha SivaSouth African Medical Research Council, HIV and Other Infectious Diseases Research Unit, Durban, South Africa.
Nishanta SinghSouth African Medical Research Council, HIV and Other Infectious Diseases Research Unit, Durban, South Africa.
Kubashni WoeberSouth African Medical Research Council, HIV and Other Infectious Diseases Research Unit, Durban, South Africa.ORCID 0000-0002-3294-4773
Zakir GaffoorSouth African Medical Research Council, HIV and Other Infectious Diseases Research Unit, Durban, South Africa.ORCID 0009-0004-8552-132X
Brenda Gati MirembeMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Flavia Matovu KiweewaMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.ORCID 0000-0002-0046-4353
Leila E MansoorCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-7607-348X
Lameck ChinulaUniversity of North Carolina Project Malawi, Lilongwe, Malawi.ORCID 0000-0003-3690-4207
Sufia DadabhaiJohns Hopkins Research Project-Kamuzu University of Health Sciences, Blantyre, Malawi.
Nelly R MugoDepartment of Global Health, University of Washington, Seattle, WA, United States.
Thesla Palanee-PhillipsWits RHI, Faculty of Health Sciences, University of the Witwatersrand, School of Public Health, Johannesburg, South Africa.ORCID 0000-0002-0052-5830
Ruanne V BarnabasDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States.ORCID 0000-0002-1793-6003
Funding
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
The Malawi Clinical Trials UnitUM1AI069518 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKY M JENNINGS, TAHA E TAHA · 2012 to 2026
$43.8M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
Bill and Melinda Gates Foundation 1200-GR0244780Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentMicrobicide Trials NetworkNational Institute of Allergy and Infectious Diseases UM1AI068615National Institute of Allergy and Infectious Diseases UM1AI068633National Institute of Allergy and Infectious Diseases UM1AI106707NIAID NIH HHS U01 AI069436NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI069518NIH HHSNIMH NIH HHS
6 · The paper itself
Abstract
backgroundObservational data on the synergy between human papillomavirus (HPV) infection and risk for HIV acquisition are needed. HPV clearance, associated with an influx of cells targeted by HIV, may increase HIV risk. This study examined the association between HPV and HIV acquisition using endocervical swabs collected in MTN-020/ASPIRE.
methodsHealthy, sexually active women without HIV participating in the ASPIRE dapivirine ring study in Malawi, South Africa, Uganda, and Zimbabwe provided endocervical swabs monthly, which were tested for HPV-DNA. HPV status was classified into prevalent, persistent (HPV+ for at least 4 months), HPV clearance (HPV+ followed by HPV-), HPV acquisition (HPV- followed by HPV+), and remaining HPV positive (2 subsequent HPV+). Cox time-varying regression models were used to assess associations between HPV states and HIV acquisition.
resultsAmong 91 HIV acquisition endpoints, HPV clearance increased HIV risk for high-risk types (16/18/31/33/35/45/52/58) (HR = 2.40, 95% CI = 1.59 to 3.62). Remaining HPV+ also showed a moderately increased risk (HR = 1.59, 95% CI = 1.07 to 2.35), while prevalent, persistent, and HPV acquisition events showed non-significant associations. Elevated HIV risk was also observed for clearance of HPV16/18, other high-risk types, low-risk types, and HPV6/11. There was also a dose-response relationship, with HIV risk increasing by 1.75-fold (95% CI = 1.55 to 1.96) for each additional HPV type cleared.
conclusionsHPV clearance-related immune activation is strongly linked to HIV acquisition, likely due to increased CD4+ T cells and inflammation. These findings support HPV vaccination as a potential HIV prevention strategy and highlight the need to integrate HIV prevention into cervical cancer programs.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Association of human papillomavirus on risk of HIV acquisition in African women: analyses from MTN-020/ASPIRE. · full record | OpenQuestion